Roche Receives European Approval for SC Formulation for MabThera

Roche reports that the European Commission (EC) has approved a new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. Following the approval of Herceptin SC in September 2013, this is the second European approval for a novel subcutaneous formulation of one of Roche's oncology products.

Roche expects to begin launching MabThera SC in a number of European markets throughout 2014.

Source: Roche

Leave a Reply

Your email address will not be published. Required fields are marked *